Status:
RECRUITING
Chemotherapy Supported by Autologous Hematopoietic Stem Cells
Lead Sponsor:
Chongqing University Cancer Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-60 years
Phase:
NA
Brief Summary
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the...
Detailed Description
Study design:In this prospective, single-center,non-randomised controlled study, patients with ovarian cancer were divided into two groups. The patients in the experimental group received autologous b...
Eligibility Criteria
Inclusion
- 1）18-60 years old; 2)there are chemotherapy indicators for ovarian cancer;3)ovarian cancer diagnosed by histopathology;4)recurrent and metastatic ovarian cancer;5)the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;6)the expected survival time was more than 3 months; 7)pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;8)all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;9)the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations;10)bone marrow function is good,ability to perform stem cell mobilisation and collection.
Exclusion
- 1\) patients with bone marrow disease;2)central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;3)patient has severe cardiac insufficiency;4)previous history of allogeneic stem cell transplantation or organ transplantation;5)patients with active bleeding and autoimmune thrombocytopenic purpura;6)patients with chemotherapy contraindications;7)positive for human immunodeficiency virus (HIV);8)acute or chronic active hepatitis B or hepatitis C infection.
Key Trial Info
Start Date :
April 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05401162
Start Date
April 15 2022
End Date
May 1 2027
Last Update
June 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030